“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.
We're tracking ST PHARM's market expansion
How ST PHARM's international expansion compares to its competitors
ST PHARMYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ST PHARMYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
STPharm, with subsidiaries Vernagen and Levatio, will present innovative RNA technologies at RNA Leaders 2024 in Basel, Switzerland on March 13-14.
STPharm held 2024 RISC symposium in Pangyo, sharing latest RNA technology and research with global experts. Over 200 attendees from industry and academia participated.
STPharm held the 2024 RNA Innovation Symposium Corea (RISC) in Pangyo, gathering about 200 RNA industry and academic experts to share latest insights.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about ST PHARM's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
